Impact of UDP-Glucuronosyltransferase 1A Haplotypes on Irinotecan Treatment

  • Kimie Sai
  • Hironobu Minami
  • Yoshiro Saito
  • Jun-ichi Sawada
Part of the Cancer Drug Discovery and Development™ book series (CDD&D)

Summary

Irinotecan, an antineoplastic-prodrug, is widely used for the treatment of colorectal, lung and other cancers, and is one of model pharmaceuticals for personalized medicine. The active metabolite, SN-38, is a topoisomerase I inhibitor generated by hydrolysis of irinotecan by carboxylesterases. SN-38 is subsequently glucuronidated by uridine diphosphate glucuronosyltransferase 1As (UGT1As) to form an inactive metabolite, SN-38 G. A reduction in SN-38 G formation is closely related to severe irinotecan toxicities (diarrhea and neutropenia). Therefore, the association of UGT1A1 polymorphisms with irinotecan toxicities has been intensively studied. A number of recent irinotecan-pharmacogenetic studies have revealed significant associations between UGT1A1*28 and severe irinotecan toxicities, leading to the introduction of the clinical application of *28 genetic testing in the United States. This paper provides an overview of recent progress in irinotecan pharmacogenetics, focusing on updated findings on the haplotype structures of UGT1As and addressing the clinical significance of UGT1A1 genotypes/haplotypes to severe irinotecan toxicities. Issues that must be addressed for improvement of personalized irinotecan therapy are also discussed.

Key Words

UGT1A1 UGT1A7 UGT1A9 pharmacogenetics irinotecan SN-38 Haplotype 

References

  1. 1.
    Garcia-Carbonero R, Supko JG, Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002; 8: 41–661.Google Scholar
  2. 2.
    Slatter JG, Su P, Sams JP et al. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos 1997;25:1157–1164.PubMedGoogle Scholar
  3. 3.
    Iyer L, King CD, Whitington PF et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998;15:847–854.CrossRefGoogle Scholar
  4. 4.
    Ciotti M, Basu N, Brangi M et al. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem Biophys Res Commun 1999;260:199–202.CrossRefPubMedGoogle Scholar
  5. 5.
    Gagne JF, Montminy V, Belanger P et al. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 2002;62:608-617.CrossRefPubMedGoogle Scholar
  6. 6.
    Oguri T, Takahashi T, Miyazaki M et al. UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers. Anticancer Res 2004;24:2893–2896.PubMedGoogle Scholar
  7. 7.
    Sparreboom A, Danesi R, Ando Y et al. harmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 2003;6:71–84.CrossRefPubMedGoogle Scholar
  8. 8.
    Nozawa T, Minami H, Sugiura S et al. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 2005;33:434–439.CrossRefPubMedGoogle Scholar
  9. 9.
    Santos A, Zanetta S, Cresteil T et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 2000;6:2012–2020.PubMedGoogle Scholar
  10. 10.
    de Forni M, Bugat R, Chabot GG et al. Phase and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 1994;54:4347–4354.PubMedGoogle Scholar
  11. 11.
    Kehrer DF, Sparreboom A, Verweij J et al. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 2001;7:1136–1141.PubMedGoogle Scholar
  12. 12.
    Gupta E, Lestingi TM, Mick R et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994;54:3723–3725.PubMedGoogle Scholar
  13. 13.
    Hanioka N, Ozawa S, Jinno H et al. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica 2001;31:687–699.CrossRefPubMedGoogle Scholar
  14. 14.
    Ando Y, Saka H, Ando M et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000;60:6921–6926.PubMedGoogle Scholar
  15. 15.
    Iyer L, Das S, Janisch L et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002;2:43–47.CrossRefPubMedGoogle Scholar
  16. 16.
    Innocenti F, Undevia SD, Iyer L et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382–1388.CrossRefPubMedGoogle Scholar
  17. 17.
    Marcuello E, Altes A, Menoyo A et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004;91:678–682.PubMedGoogle Scholar
  18. 18.
    Rouits E, Boisdron-Celle M, Dumont A et al. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004;10:5151–5159.CrossRefPubMedGoogle Scholar
  19. 19.
    Judson R, Stephens JC, Windemuth A. The predictive power of haplotypes in clinical response. Pharmacogenomics 2000;1:15–26.CrossRefPubMedGoogle Scholar
  20. 20.
    Mackenzie PI, Bock KW, Burchell B et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 2005;15:677–685.CrossRefPubMedGoogle Scholar
  21. 21.
    Radominska-Pandya A, Czernik PJ, Little JM et al. Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 1999;31:817–899.CrossRefPubMedGoogle Scholar
  22. 22.
    Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000;40:581–616.CrossRefPubMedGoogle Scholar
  23. 23.
    Finel M, Li X, Gardner-Stephen D et al. Human UDP-glucuronosyltransferase 1A5: identification, expression, and activity. J Pharmacol Exp Ther 2005;315:1143–1149.CrossRefPubMedGoogle Scholar
  24. 24.
    Basu NK, Ciotti M, Hwang MS et al. Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem 2004;279:1429–1441.CrossRefPubMedGoogle Scholar
  25. 25.
    Bosma PJ, Chowdhury JR, Bakker C et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995;333:1171–1175.CrossRefPubMedGoogle Scholar
  26. 26.
    Monaghan G, Ryan M, Seddon R et al. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996;347:578–581.CrossRefPubMedGoogle Scholar
  27. 27.
    Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 1998;95:8170–8174.CrossRefPubMedGoogle Scholar
  28. 28.
    Sugatani J, Yamakawa K, Yoshinari K et al. Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem Biophys Res Commun 2002;292:492–497.CrossRefPubMedGoogle Scholar
  29. 29.
    Aono S, Yamada Y, Keino H et al. Identification of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler–Najjar syndrome type II. Biochem Biophys Res Commun 1993;197:1239–1244.CrossRefPubMedGoogle Scholar
  30. 30.
    Aono S, Adachi Y, Uyama E et al. Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome. Lancet 1995;345:958–959.CrossRefPubMedGoogle Scholar
  31. 31.
    Jinno H, Tanaka-Kagawa T, Hanioka N et al. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos 2003;31:108–113.CrossRefPubMedGoogle Scholar
  32. 32.
    Guillemette C, Ritter JK, Auyeung DJ et al. Structural heterogeneity at the UDP-glucuronosyl- transferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 2000;10:629–644.CrossRefPubMedGoogle Scholar
  33. 33.
    Yamanaka H, Nakajima M, Katoh M et al. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 2004;14:329–332.CrossRefPubMedGoogle Scholar
  34. 34.
    Villeneuve L, Girard H, Fortier LC et al. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 2003;307:117–128.CrossRefPubMedGoogle Scholar
  35. 35.
    Jinno H, Saeki M, Saito Y et al. Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients. J Pharmacol Exp Ther 2003;306:688–693.CrossRefPubMedGoogle Scholar
  36. 36.
    Jinno H, Saeki M, Tanaka-Kagawa T et al. Functional characterization of wild-type and variant (T202I and M59I) human UDP-glucuronosyltransferase 1A10. Drug Metab Dispos 2003;31:528–532.CrossRefPubMedGoogle Scholar
  37. 37.
    Innocenti F, Grimsley C, Das S et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 2002;12:725–733.CrossRefPubMedGoogle Scholar
  38. 38.
    Sai K, Saeki M, Saito Y et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004;75:501–515.CrossRefPubMedGoogle Scholar
  39. 39.
    Kaniwa N, Kurose K, Jinno H et al. Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American. Drug Metab Dispos 2005;33:458–465.CrossRefPubMedGoogle Scholar
  40. 40.
    Saeki M, Saito Y, Jinno H et al. Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics J 2006;6:63–75.CrossRefPubMedGoogle Scholar
  41. 41.
    Han JY, Lim HS, Shin ES et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006;24:2237–2244.CrossRefPubMedGoogle Scholar
  42. 42.
    Kohle C, Mohrle B, Munzel PA et al. Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians. Biochem Pharmacol 2003;65:1521–1527.CrossRefPubMedGoogle Scholar
  43. 43.
    Carlini LE, Meropol NJ, Bever J et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005;11:1226–1236.PubMedGoogle Scholar
  44. 44.
    Innocenti F, Liu W, Chen P et al. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet Genomics 2005;15:295–301.CrossRefPubMedGoogle Scholar
  45. 45.
    Girard H, Villeneuve L, Court MH et al. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab Dispos 2006;34:1220–1228.CrossRefPubMedGoogle Scholar
  46. 46.
    Maitland ML, Grimsley C, Kuttab-Boulos H et al. Comparative genomics analysis of human sequence variation in the UGT1A gene cluster. Prmacogenomics J. 2006;6:52–62.CrossRefGoogle Scholar
  47. 47.
    Minami H, Sai K, Saeki M et al. Irinotecan pharmacokineitcs/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: Roles of UGT1A1*6 and *28. Pharmacogenet Genomics 2007;17: 497–504.CrossRefPubMedGoogle Scholar
  48. 48.
    Araki K, Fujita K, Ando Y et al. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 2006;97: 1255–1259.CrossRefPubMedGoogle Scholar
  49. 49.
    Kitagawa C, Ando M, Ando Y et al. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity. Pharmacogenet Genomics 2005;15:35–41.CrossRefPubMedGoogle Scholar
  50. 50.
    Saeki M, Saito Y, Sai K et al. A combinatorial haplotype of the UDP-glucuronosyltransferase 1A1 gene (#60–#IB) increases total bilirubin levels in Japanese. Clin Chem 2007;53:356–358.CrossRefPubMedGoogle Scholar
  51. 51.
    Girard H, Court MH, Bernard O et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 2004;14:501–515.CrossRefPubMedGoogle Scholar
  52. 52.
    Paoluzzi L, Singh AS, Price DK et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 2004;44:854–860.CrossRefPubMedGoogle Scholar
  53. 53.
    Ando M, Ando Y, Sekido Y et al. Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese Cancer Patients. Jpn J Cancer Res 2002;93:591–597.PubMedGoogle Scholar
  54. 54.
    Font A, Sanchez JM, Taron M et al. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest New Drugs 2003;21:435–443.CrossRefPubMedGoogle Scholar
  55. 55.
    Toffoli G., Cecchin E, Corona G et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin.Oncol 2006;24:3061–3068.Google Scholar
  56. 56.
    Sai K, Kaniwa N, Itoda M et al. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 2003;13:741–757.CrossRefPubMedGoogle Scholar
  57. 57.
    Xiang X, Jada SR, Li HH et al. Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet Genomics 2006;16:683–691.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Kimie Sai
    • 1
  • Hironobu Minami
  • Yoshiro Saito
  • Jun-ichi Sawada
  1. 1.Division of BiosignalingNational Institute of Health SciencesTokyoJapan

Personalised recommendations